{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:42Z","timestamp":1760189382472},"reference-count":31,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.3892\/mco.2014.314","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T13:37:28Z","timestamp":1402580248000},"page":"656-660","source":"Crossref","is-referenced-by-count":21,"title":["Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review)"],"prefix":"10.3892","volume":"2","author":[{"given":"MICHAEL D.","family":"WEINTRAUB","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QINGDI QUENTIN","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PIYUSH K.","family":"AGARWAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"key20180107150839_b1-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"key20180107150839_b2-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"key20180107150839_b3-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","article-title":"Evaluation and follow-up strategies for superficial bladder cancer","volume":"30","author":"Donat","year":"2003","journal-title":"Urol Clin North Am"},{"key":"key20180107150839_b4-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","volume":"53","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"key20180107150839_b5-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1464-410X.2006.06144.x","article-title":"The value of a second transurethral resection for T1 bladder cancer","volume":"97","author":"Schwaibold","year":"2006","journal-title":"BJU Int"},{"key":"key20180107150839_b6-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J Urol"},{"key":"key20180107150839_b7-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 3","key":"key20180107150839_b8-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer","volume":"31","author":"Lamm","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key20180107150839_b9-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J Control Release"},{"key":"key20180107150839_b10-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/0008-5472.CAN-12-1871","article-title":"Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth","volume":"72","author":"Kang","year":"2012","journal-title":"Cancer Res"},{"key":"key20180107150839_b11-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"key20180107150839_b12-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/1078-0432.CCR-10-2981","article-title":"In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer","volume":"17","author":"Mugabe","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107150839_b13-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107150839_b14-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Gu\u00e9rin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"key20180107150839_b15-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000098076","article-title":"Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder","volume":"78","author":"Buscarini","year":"2007","journal-title":"Urol Int"},{"key":"key20180107150839_b16-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"key20180107150839_b17-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"key20180107150839_b18-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"key20180107150839_b19-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor - armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107150839_b20-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"key20180107150839_b21-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer","volume":"2","author":"Seager","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"key20180107150839_b22-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","article-title":"Inactivation of p53 and Pten promotes invasive bladder cancer","volume":"23","author":"Puzio-Kuter","year":"2009","journal-title":"Genes Dev"},{"key":"key20180107150839_b23-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cgt.2010.50","article-title":"Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma","volume":"18","author":"Zhang","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"key20180107150839_b24-mco-02-05-0656","first-page":"5647","article-title":"Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder","volume":"59","author":"Mohammed","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107150839_b25-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J Urol"},{"key":"key20180107150839_b26-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1517\/13543784.10.12.2157","article-title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","volume":"10","author":"Filion","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180107150839_b27-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"key20180107150839_b28-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ucl.2013.01.008","article-title":"New agents for bacillus Calmette-Gu\u00e9rin-refractory bladder cancer","volume":"40","author":"Ahn","year":"2013","journal-title":"Urol Clin North Am"},{"key":"key20180107150839_b29-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1464-410X.2010.10056.x","article-title":"The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands","volume":"108","author":"Miyazaki","year":"2011","journal-title":"BJU Int"},{"key":"key20180107150839_b30-mco-02-05-0656","first-page":"2065","article-title":"The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma","volume":"31","author":"Miyazaki","year":"2011","journal-title":"Anticancer Res"},{"key":"key20180107150839_b31-mco-02-05-0656","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.urolonc.2008.12.017","article-title":"The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer","volume":"28","author":"Andrade","year":"2010","journal-title":"Urol Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2014.314\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T15:08:52Z","timestamp":1515337732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2014.314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,6,12]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.3892\/mco.2014.314"],"URL":"https:\/\/doi.org\/10.3892\/mco.2014.314","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}